Tout­ing CD161 as a test case for sin­gle-cell tech, Long­wood-backed Im­mu­ni­tas bags $58M for next-gen I/O work

Back when Long­wood un­veiled its lat­est im­munother­a­py start­up, Im­mu­ni­tas, the VC’s co-founder Lea Hachi­gian talked at length about how its sin­gle-cell ge­nomics analy­sis plat­form could …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER